TGA's approval of MDMA and Psilocybin for medical use is a result of ‘renewed interest’ скачать в хорошем качестве

TGA's approval of MDMA and Psilocybin for medical use is a result of ‘renewed interest’

Neuromedicines Discovery Centre Deputy Director Professor Chris Langmead says the Therapeutics Goods Administration’s recent approval for MDMA and Psilocybin is a result of a “renewed interest”. “There has been a renewed interest in looking at substances such as MDMA and psilocybin for many years - in fact, much work was done in the 1960s,” he told Sky News Australia. “But it really is only in the last two or three or four years that there’s been significantly large clinical trials that have studied the effectiveness of MDMA when used combined with psychotherapy for the treatment of PTSD. “Or psilocybin when combined with psychotherapy for the treatment of very difficult to treat depression. “It is the large amount of emerging clinical data around the safety and the effectiveness of these medicines when used under very strictly controlled clinical conditions that has led the TGA to make this decision.”